Smith & Nephew plc vs Under Armour Inc Class A — how do they compare? Smith & Nephew plc trades at $29.68 (market cap $12.54B), while Under Armour Inc Class A trades at $5.16 (market cap $2.26B). The key difference: Smith & Nephew plc is far larger — about 5.5× Under Armour Inc Class A's market cap, and Smith & Nephew plc pays a 2.65% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| SNN | UA | |
|---|---|---|
Market Cap | $12.54B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $38.70 | $7.88 |
52-Week Low | $28.73 | $3.96 |
Enterprise Value | $15.57B | $3.24B |
Dividend Yield | 2.65% | — |
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
Under Armour (UA) trades at $5.20, down 8.37% amid weak quarterly results and lowered revenue guidance. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal declining revenue ($5.16B in 2025 to $4.9B in 2026) and negative profitability (net margin -9.99%). Recent news highlights softer consumer demand in key markets, though the company maintains its profitability outlook.
The outlook remains challenging with significant execution risks and competitive pressures. While analyst sentiment is mixed (38.81% Buy, 49.25% Hold), the stock's deep value metrics (P/S 0.45) may attract contrarian investors if operational improvements materialize. Key risks include sustained revenue declines and negative cash flow trends.
Trailing returns across standard periods
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →